MIRM — Mirum Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.61bn
- $5.92bn
- $521.31m
Mirum Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Brief: Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
Brief: Mirum Submits New Drug Application To FDA For Chenodiol For The Treatment Of CTX
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
Brief: Mirum Pharmaceuticals Announces Interim Data For Volixibat From VANTAGE PBC And VISTAS PSC Studies
Brief: Mirum Pharmaceuticals Announces Positive CHMP Opinion For Livmarli® (Maralixibat) Oral Solution For The Treatment Of Pfic In Patients Three Months Of Age And Older
U.S. RESEARCH ROUNDUP- Crescent Energy, Rockwell Automation, Transdigm Group
Brief: Mirum Pharmaceuticals Q1 Basic EPS USD -0.54
Mirum Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Sagimet Biosciences Announces Appointment Of Tim Walbert And Paul Hoelscher To Board Of Directors
U.S. STOCKS ON THE MOVE-G-III Apparel Group, Tesla, MicroStrategy
U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Build-A-Bear, Spruce Biosciences
U.S. STOCKS ON THE MOVE-Netflix, RTX, Dollar General
Mirum Pharma rises on expanded approval for liver disease drug
U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
US FDA approves expanded use of Mirum's liver disease drug (updated)